Ulixertinib
Recurrent Malignant Germ Cell Tumor
National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
24 Active assets in the Recurrent Malignant Germ Cell Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Children's Oncology Group | Phase 3 | BB |
ETOPOSIDE Children's Oncology Group | Phase 3 | BB |
Eloxatin National Cancer Institute (NCI) | Phase 2 | BB |
FILGRASTIM Children's Oncology Group | Phase 2 | B |
BLEOMYCIN Children's Oncology Group | Phase 3 | B |
View all 35 →
Same molecule, other indications
Ulixertinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →